- Apr 30, 2018
The protocol is being used in 4 clinical trials run by the NCRI. Whether or not it’s recognized by a regulatory agency as an endpoint, it can allow researchers to discard ineffective compounds/recognize potential treatments earlier in the process.Note: there is frequently a long time between a new prognostic marker's development and the FDA or any other regulatory agency's accepting it as a surrogate endpoint. Even as a diagnostic aid or means to monitor disease progression, you also have to look at how costly/difficult it would be for other centers to implement the protocol and the point at which payors will fund it. Still, progress is being made.